Insider · CIK 0001727727
Ilan Hadar
Files at SLXN (Silexion Therapeutics Corp). First filing -, latest -.
In brief
Ilan Hadar files SEC Form 4 as CEO, chair and director at SLXN (Silexion Therapeutics Corp). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Ilan Hadar has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 4, 2026 | SLXN Silexion Therapeutics Corp | AGrant or award Ordinary Shares | +10,000 | $0.00 | $0 | 16,547 | Jun 8, 2026 |
| Feb 20, 2026 | SLXN Silexion Therapeutics Corp | AGrant or award Ordinary Shares | +64,350 | $0.00 | $0 | 65,471 | Feb 23, 2026 |
Questions about Ilan Hadar
Answered from the filings on this page, as of the latest one.
Is Ilan Hadar buying or selling?
Ilan Hadar has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Ilan Hadar's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Ilan Hadar has 0.
Where does Ilan Hadar file Form 4?
Ilan Hadar has filed Form 4 at SLXN (Silexion Therapeutics Corp) as Chairman and CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.